Evidence map›Paper›PMID 38339799›Full record

Trial reportPediatric obesity2024

Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP-1RA therapy in adolescents with severe obesity.

Megan O Bensignor, Aaron S Kelly, Alicia Kunin-Batson, Claudia K Fox, Rebecca Freese, Justin Clark, Kyle D Rudser, Eric M Bomberg, Justin Ryder, Amy C Gross

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatric obesity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Observational
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Megan O BensignorDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-9341-1858
Aaron S KellyDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
Alicia Kunin-BatsonDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-7607-5602
Claudia K FoxDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0001-5732-0062
Rebecca FreeseClinical and Translational Science Institute, Biostatistical Design and Analysis Center, University of Minnesota, Minneapolis, Minnesota, USA.
Justin ClarkDivision of Biostatistics and Health Data Science, University of Minnesota School of Public Health, Minneapolis, Minnesota, USA.
Kyle D RudserCenter for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Eric M BombergDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-8037-4314
Justin RyderDepartment of Pediatrics and Surgery, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
Amy C GrossDepartment of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0003-2809-8460
University of Minnesota Medical Center · USUniversity of Minnesota · USNorthwestern University · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Enhancing Weight Loss Maintenance with GLP-1 in Adolescents with Severe ObesityR01DK105953 · NIDDK · UNIVERSITY OF MINNESOTA · PI KELLY, AARON S · 2015 to 2019
$3.1M
Precision Medicine Approaches to Obesity Pharmacotherapy in Youth with Severe ObesityK23DK125668 · NIDDK · UNIVERSITY OF MINNESOTA · PI BOMBERG, ERIC MORRIS · 2020 to 2024
$1.0M
Anti-obesity pharmacotherapy to decrease BMI and improve insulin sensitivity in adolescents with obesity and type 2 diabetesK23DK129721 · NIDDK · UNIVERSITY OF MINNESOTA · PI BENSIGNOR, MEGAN O · 2021 to 2025
$1.0M
NCATS NIH HHS UL1 TR002494NIDDK NIH HHS K23 DK125668NIDDK NIH HHS K23 DK129721NIDDK NIH HHS R01 DK105953NIH HHS K23DK125668NIH HHS K23DK129721NIH HHS R01DK105953
6 · The paper itself

Abstract

introductionWhilst glucagon-like peptide-1 receptor agonists (GLP1-RAs) are effective for treating adolescent obesity, weight loss maintenance (WLM; preventing weight regain) remains a challenge. Our goal was to investigate appetite/satiety hormones and eating behaviours that may predict WLM with exenatide (a GLP1-RA) versus placebo in adolescents with severe obesity.

methodsAdolescents who had ≥5% body mass index (BMI) reduction with meal replacement therapy were randomized to 52 weeks of once-weekly exenatide extended release or placebo. In this secondary analysis, eating behaviours and appetite/satiety regulation hormones post-meal replacement therapy (pre-randomization to exenatide or placebo) were evaluated as possible predictors of WLM. Percent change in BMI from randomization to 52 weeks served as the primary measure of WLM.

resultsThe analysis included 66 adolescents (mean age 16.0 years; 47% female). Lower leptin response to meal testing was associated with greater WLM in terms of BMI percent change in those receiving exenatide compared to placebo (p = 0.007) after adjusting for sex, age and BMI. There were no other significant predictors of WLM.

conclusionsPrior to exenatide, lower leptin response to meals was associated with improved WLM with exenatide compared to placebo. The mostly null findings of this study suggest that GLP1-RA treatment may produce similar WLM for adolescents with obesity regardless of age, BMI, sex and eating behaviours.

Indexed as

Diabetes Mellitus, Type 2Obesity, MorbidPediatric ObesityAdolescentAppetiteExenatideFeeding BehaviorFemaleHumansHypoglycemic AgentsLeptinMaleWeight LossExenatideHypoglycemic AgentsLeptinappetiteglucagon‐like peptide‐1 receptor agonistpediatric obesitypharmacotherapyweight regain

Identifiers

PMID38339799
PMCPMC11006569
OpenAlexW4391718444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.